Purpose: The criteria for identifying lung cancer patients with metastatic spinal cord compression (MSCC) who may benefit from decompressive surgery remains unclear. This study aims to create a new therapeutic strategy which can guild surgeons to select the individual treatment for MSCC patients from lung cancer. Methods: We retrospectively assessed 73 consecutive lung cancer patients who were treated with decompressive surgery for MSCC. Twelve preoperative characteristics were analyzed for postoperative survival. Characteristics significantly associated with survival in the multivariate analyses were included in a scoring system. The total score for each patient was obtained by adding the scoring points of all significant characteristics. Postoperative function outcome was also analyzed according to prognostic groups. Results: In the multivariate analyses, preoperative ambulatory status (P ¼ 0.02), targeted therapy (P ¼ 0.01), number of involved vertebrae (P < 0.01), visceral metastases (P < 0.01), and time developing motor deficits (P < 0.01) had significant impact on survival and were included in the scoring system. According to the prognostic scores, which ranged from 15 to 35 points, three prognostic groups were designed: 15e23 points (n ¼ 32), 25e29 points (n ¼ 26), and 31e35 points (n ¼ 15). The corresponding median survival times were 2.6 months (95% CI, 1.5e4.3 months), 7.2 months (95% CI, 6.0e10.8 months) and 13.2 months (95% CI, 8.8e18.7 months), respectively (P < 0.01), and the corresponding postoperative ambulatory rates were 46.9%, 80.8%, and 93.3%, respectively (P < 0.01). Conclusion: We present a scoring system for lung cancer patients with MSCC after surgery based on survival and functional outcome. The scoring system can guild surgeons to select the individual strategy for patients with MSCC from lung cancer.
Introduction
Metastatic spinal cord compression (MSCC) is radiographically defined as an epidural metastatic lesion causing true displacement of the spinal cord from its normal position, which is an essential source of morbidity in patients with systemic advanced cancer. MSCC can result in paralysis, bowel and bladder disorders with a highly negative impact on patient's quality of life. 1 Approximately 28% of patients with lung cancer are estimated to develop MSCC during their disease course, 2 and MSCC secondary to lung cancer has worse prognosis compared to MSCC related to other solid tumors. 3 Individual strategies are particularly important for patients with MSCC, especially for patients with MSCC resulted from lung cancer. However, the standard treatment for MSCC remains controversial. In 2005, a randomized trial (n ¼ 101) showed that decompressive surgery following by radiotherapy was superior to radiation alone. 4 But more recently, Rades et al. 5 did not find any benefit of surgery following by radiotherapy when compared with radiotherapy alone in a matched pair analyses (n ¼ 324).
Moreover, the criteria for identifying patients with MSCC who may benefit from decompressive surgery is still unclear, let alone especially for identifying lung cancer patients with MSCC. Recently, only a few studies specifically addressed surgical treatment of MSCC in lung cancer. 6e8 Several scoring systems have been proposed to assess survival prognosis for spinal metastasis from various primary tumors. 9e15 The most currently used scores are those developed by Tokuhashi et al. 9 and Tomita et al. 12 Both recommend that treatment strategy be based on survival prognosis. However, these scores were developed in retrospective studies comprising relatively small number of patient with lung cancer, making it difficult to draw conclusions on this specific tumor entity. Each tumor entity leading to spinal metastasis and consequent MSCC has its own biological behavior and metastatic patterns, so a score for each tumor entity is really needed, and only if specific scores are available for each of these entities can optimal treatment personalization be realized. Besides, several studies strongly suggested that some old and commonlyused scoring systems have underestimated the life expectancy of patients with spinal metastases of lung cancer due to the increased survival time in recent years. 16, 17 Furthermore, the choice of survival duration as a unique criterion in those scoring systems for patient selection can be challenged because quality of life and functional outcome are also of utmost importance in the metastatic background.
Therefore, our present study is designed to develop a survival score and analyze functional outcome particularly for patients with MSCC from lung cancer to help select individual strategy for those patients.
Patients and methods

Patients
Seventy-three patients with lung cancer who were operated with decompression and spine stabilization for MSCC were retrospectively analyzed in the study at the Affiliated Hospital The postoperative survival was defined as the time between the date of surgery and death or the latest followup. For the present study, we included all 73 patients with lung cancer who had decompressive surgery and spine stabilization due to spinal cord compression. None of the patients were excluded for any reason. Eight patients were still alive by the end of the study period, with a mean follow-up of 7.6 months in those patients. In patients who had surgery for more than one metastasis, all sites were included in the analyses. However, only the first surgical procedure was accounted for in the survival analyses.
Surgery and functional evaluation
The indication for surgery was neurological deficit due to MSCC. All patients were operated with decompression and spine stabilization (Fig. S1 , a case report). Local radiotherapy, systemic chemotherapy, and targeted therapy with gefitinib were performed after the wound healed, about 3e4 weeks after the surgery. Postoperative functional outcome was analyzed according to the scoring system. Neurological function was graded based on Frankel score preoperatively and 4 weeks postoperatively (Patients with Frankel D and E have the ability to walk). Ambulatory status was defined that a patient could take at least two steps with each foot unassisted, even if a cane or walker was needed, which was developed from Patchell et al. 4 Time developing motor deficits defined as the time between deterioration of motor function to disability or surgery. Deterioration of motor function was defined as a change of at least one Frankel grade.
Statistical analyses
The univariate and multivariate analyses of postoperative survival were performed using the KaplaneMeier method and Cox proportion hazards model, respectively. The prognostic factors that were significant in the multivariate analyses were included in the scoring system. The score for each significant prognostic factor was calculated by dividing the 6-month survival rate (in %) by 10. 15 The total prognostic score for each patient was determined by adding the scoring points of every significant factor. Neurological outcome in risk groups was compared with Chisquare test. A P value of 0.05 or less was considered statistically significant. Statistical analyses were performed using SAS 9.2 software.
Results
Survival
In the entire cohort of 73 patients, the overall median survival time was 6.0 months (95% CI, 4.5e7.1 months), 6-month and 12-month survival rates were 49% and 22%, respectively. At the latest follow-up, eight patients were still alive, with a mean follow-up of 7.6 months (1.5e39.0 months).
Development of a new score
In the univariate analyses, survival was significantly associated with preoperative ambulatory status (HR, 1.95, 95% CI: 1.17e3.25; P ¼ 0.01), targeted therapy (HR, 2.38, 95% CI: 1.39e4.08; P < 0.01), ECOG performance status (HR, 2.57, 95% CI: 1.47e4.49; P < 0.01), number of involved vertebrae (HR, 2.81, 95% CI: 1.62e4.85; P < 0.01), visceral metastases (HR, 2.55, 95% CI: 1.52e4.28; P < 0.01), and time developing motor deficits (HR, 3.70, 95% CI: 2.09e6.57; P < 0.01) (Fig. S2 , Table  1 ). According to the multiple Cox proportional hazards model, five of above six factors, preoperative ambulatory status (HR, 1.93, 95% CI: 1.12e3.34; P ¼ 0.02), targeted therapy (HR, 2.13, 95% CI: 1.19e3.82; P ¼ 0.01), number of involved vertebrae (HR, 2.36, 95% CI: 1.32e4.22; P < 0.01), visceral metastases (HR, 2.33, 95% CI: 1.31e4.14; P < 0.01), and time developing motor deficits (HR, 2.38, 95% CI: 1.27e4.46; P < 0.01) maintained significant impact on survival and were included in the scoring system ( Table 1 ). The scoring points for each of the five significant factors obtained from the 6-month survival rates were seen in Table 2 . The prognostic score for each patient was calculated by adding the scoring points of the five significant characteristics. The addition resulted in prognostic scores of 15, 17, 19, 21, 23, 25, 27, 29, 31 , 33, 35 points. The 6-month survival rates, median overall survival time, and the total number of patients of each prognostic score were shown in Fig. 1 . Taking into account the 6-month survival rates and median overall survival time of the prognostic scores, the following three survival groups were formed: 15e23 points (group A, n ¼ 32), 25e29 points (group B, n ¼ 26), and 31e35 points (group C, n ¼ 15, 5 patients were still alive). The corresponding median survival times were 2.6 months (95% CI, 1.5e4.3 months), 7.2 months (95% CI, 6.0e10.8 months) and 13.2 months (95% CI, 8.8e18.7 months), 6-month survival rates were 9.9%, 70.0% and almost 100.0%, respectively, and 12-month survival rates were 0.0%, 22.9%, and 64.3%, respectively (P < 0.01, Fig. 2 ).
Functional outcome
The functional outcome was worse in the group of patient with 15e23 points (group A) when compared with the other two prognostic groups (Table 3 ). In detail, only 46.9% (15/32) patients were able to walk (Frankel D/E) 4 weeks after surgery in group A, 80.8% (21/26) patients in group B, and 93.3% (14/15) patients in group C (P ¼ 0.0015).
In the entire cohort of 73 patients, 68.5% (50 of 73) patients were able to walk 4 weeks after decompression, 8 patients died within 4 weeks after surgery and none of them achieved ambulatory status. 51.5% (17/33) of nonambulatory patients (Frankel B/C) before operation regained the ability to walk. 82.5% (33/40) of ambulatory patients maintained their neurological status, whereas 17.5% (7/44) of ambulatory patients before surgery lost their ability to walk for disease progression (4 patients) and postoperative complication (3 patients).
Discussion
Currently, the most appropriate treatment for MSCC is still controversial. A phase III trial strongly suggested that direct decompressive surgery followed postoperative radiotherapy was superior to treatment with radiotherapy alone for MSCC in 2005. 4 However, Rades et al. 5 proposed the opposite result in 2010, the outcome of radiotherapy alone was not significantly inferior to those of surgery plus radiotherapy. Generally speaking, radiation and surgical decompression are both accepted and effective, and there appears to be a favorable trend for improved neurological outcome with surgical decompression and stabilization as part of the management. 4, 18 The choice of radiotherapy alone or surgery in MSCC depends on accurate patient selection. Selection of the optimal treatment for the individual patient should take into account patient's estimated survival time and functional outcome after therapies. 19, 20 Patients with very short survival time and poor functional outcome appear to be best treated with radiotherapy, or even best supportive care alone, which means less discomfort for these debilitated and enervated patient. In contrast, patient with a more favorable survival prognosis and functional outcome may benefit from surgery, which facilitates better local control of disease. 20 Selection of individual strategy can be estimated with the help of significant prognostic factors and scoring systems.
Prognostic factors
Previously, in a retrospective study, we found that postoperative survival was significantly associated with type of primary tumor, preoperative ambulatory status, visceral metastasis, and targeted therapy. Metastatic location, preoperative ambulatory status, and time developing motor deficit had significant impact on postoperative functional outcome. 21 However, those significant factors were not particularly for patients with MSCC resulted from lung cancer. Several other prognostic factors have been identified to have statistically significant associations with survival.
Better postoperative ambulatory status, improvement in neurologic status after surgery, and postoperative radiotherapy were significant associated with longer survival which have been shown in some studies. 6, 7 However, those significant factors were in postoperative level, making it nonsense to determine whether surgical treatment is appropriate for patients before surgery.
In the present study, we analyzed twelve preoperative characteristics. Preoperative ambulatory status, targeted therapy, ECOG performance status, number of involved vertebrae, visceral metastases, and time developing motor deficit had significant impact on survival in univariate analyses. According to the multiple Cox proportional hazards model, five of above six significant factors, preoperative ambulatory status, targeted therapy, number of involved vertebrae, visceral metastases, and time developing motor deficits, maintained significant impact on survival, which was in accordance with other studies.
2,3,6,10,21 ECOG performance status was significant associated with survival in univariate analyses, which was in line with Tokuhashi et al., 9, 11 while it was excluded by the Cox proportional hazards model. So ECOG performance status was not included in the scoring system. Postoperative ambulatory status was strongly related to preoperative ambulatory status, 21, 22 which was included in our scoring system.
Scoring systems
Various scoring systems have been proposed for patient with spinal metastasis on the basis of retrospective data from relatively small number of lung cancer patients treated with surgery or radiotherapy alone. In 1990, Tokuhashi et al. 9 presented a score which is mostly used based on the data of 64 patients with a metastatic spine tumor who underwent spinal surgery, and only 6 patients had lung cancer (More details were seen in Supplementary table). In 1995, Sioutos et al. 10 developed a score that comprised 109 patients, including 45 lung cancer patients. Ten years later, Tokuhashi has revised their score in a series of 246 patient, and rarely 26 patients with lung cancer. Notably, 33.3% of participants were not treated with surgery in Tokuhashi's study. 11 The revised Tokuhashi was found to be very useful to predict survival for patients with spinal metastases from breast cancer alone 23 or solid cancers. 24, 25 Unfortunately, the revised Tokuhashi score which seems to be a suboptimal tool for the prediction of individual prognosis in the group of lung cancer patients has been shown in the study of Hessler et al. 16 in 2011. In their study, 67 patients with spinal metastasis from lung cancer, all of them underwent surgical treatment, and Hessler et al. 16 concluded that the Tokuhashi scoring system underestimated the life expectancy of patients with lung cancer due to the increased survival time for this patient group. In 2013, Morgen et al. 17 also found a statistically significant increase in survival over the years for More recent study has reported that only 8.6% patients actually followed the survivorship pattern as predicted by Tokuhashi score in a series of 151 patients with spine metastases from primary lung cancer. 26 Therefore, with the increasing survival time of patients with lung cancer during recent years, the accuracy of the Tokuhashi score was decreasing over time.
27e29 Furthermore, these scores were designed for patients with spinal metastasis in general, not particularly for patients with motor impairment due to MSCC. Rades et al. 15 developed and validated a scoring system for survival of patients (n ¼ 356, all patients with lung cancer) with MSCC from non-small cell lung cancer who had been treated with radiotherapy alone. Apart from the Rades score, above scoring systems included relatively small number of patients with spinal metastasis from various primary tumors. In fact, participants in Rades score were received radiotherapy alone, and the functional outcome was not considered either. Moreover, patients had prior surgery to the involved parts of the spinal cord were excluded in their study.
In our study, a score was developed based on the data derived from 73 patients with lung cancer who underwent decompressive surgery and spine stabilization for MSCC. The indication for surgery was neurological deficits due to MSCC. The patient's individual situation, therefore, was taken more into account in the present scoring system. Patients with scores of 15e23 points, who survived less than 3 months in median time and had the worst functional outcome after surgery compared with other two prognostic groups, appeared to be best treated with radiotherapy or best supportive care alone. Patients with scores of 25e29 points should be surgical candidates, because survival prognosis and functional outcome are favorable after surgery. Patients with scores of 31e35 survived more than 1 year in median time, and 93.3% patients were ambulatory after surgery. More radical surgery, such as widely excision of vertebra metastasis, could be considered in order to realize better control of local disease and prevent the occurrence of local disease. Functional outcome was acceptable in the entire cohort of 73 patients, 68.5% (50 of 73) patients were able to walk 4 weeks after surgery; 51.5% (17/33) of nonambulatory patients before operation regained the ability to walk. 74e84% patients were able to walk after surgery 4, 6 and 22e68% of nonambulatory patients became ambulatory again in other studies. 6, 8, 30, 31 However, our score was based on retrospective data, the statistical analyses not included a relatively larger number of patients, and data on systemic treatment following treatment was not available in most patients. Moreover, patients with asymptomatic MSCC were not included in our study, so this scoring system might not be suitable for those patients, and the duration from symptoms to surgery may be a confounding factor that could bias survival outcome and surgical results. Therefore, despite good predictive value in our scoring system, the score still warrants a prospective study to be confirmed.
Conclusion
We present a new score for predicting survival and functional outcome of patients with lung cancer after decompressive surgery. The scoring system can help select the individual strategy for patients with MSCC from lung cancer. Patients with scores of 15e23 points have short survival time and poor functional outcome after surgery. Radiotherapy or best supportive care alone may be considered in most patients of this group. Patients with scores of 25e29 points should be surgical candidates, because survival prognosis and functional outcome are acceptable after surgery. Patients with scores of 31e35, who have the most favorable survival prognosis and functional outcome, can be treated with more radical surgery in order to realize better control of local disease and prevent the occurrence of local disease. Still, a prospective study is needed. 
